

ASX Release

30<sup>th</sup> March 2015

## JOINT PATENT WITH JAPANESE COMPANY NOW PUBLISHED

**PharmAust Limited** (“PharmAust”) (ASX: PAA & PAAO) is pleased to report that further to a research collaboration which began in July 2013 with a Japanese Corporation, a Joint Patent has now been published (**Patent Number:** WO/2015/037747) describing an invention on a series of analogues of PPL-1 (monepantel). The joint Intellectual Property (IP) allows PharmAust access to some 80 analogues of PPL-1, which have been synthesised by the Japanese Corporation and tested for anticancer activity by PharmAust. The Joint Patent Application permits PharmAust to commercialise the analogues subject to other prevailing IP at the time of commercialisation. This collaboration broadens and strengthens PharmAust’s IP position.

PharmAust’s Executive Chairman, Dr Roger Aston said, “The commercialisation of aminoacetonitriles in cancer, of which PPL-1 is a key approved product for treatment of veterinary diseases, is PharmAust’s principal activity at the present time. PharmAust currently has a Collaborative Research and Option Agreement with one of the top five major global pharmaceutical companies for the development and commercialization of PPL-1 in veterinary cancers. Our recent success in demonstrating meaningful reductions of blood cancer markers in late stage cancer patients who have failed standard of care, gives us further confidence that we are on track with our commercialization pathway.”

**For further details please contact:**

**Dr Roger Aston**  
**Executive Chairman**  
**PharmAust Limited**  
**Tel: 0402 762 204**

[www.pharmaust.com](http://www.pharmaust.com)